Have a feature idea you'd love to see implemented?
Let us know!
PTCT Ptc Therapeutics Inc
Price (delayed)
$46.24
Market cap
$3.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.94
Enterprise value
$3.44B
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally
Highlights
The company's debt fell by 43% YoY
The EPS is up by 31% year-on-year and by 6% since the previous quarter
The quick ratio has surged by 112% year-on-year but it has declined by 5% since the previous quarter
Ptc Therapeutics's equity has shrunk by 57% YoY and by 8% QoQ
The gross margin has declined by 2% year-on-year
Key stats
What are the main financial stats of PTCT
Market
Valuations
Earnings
Shares outstanding
77.13M
Market cap
$3.57B
Enterprise value
$3.44B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.82
Revenue
$900.66M
Gross profit
$830.43M
Net income
-$453.2M
EBIT
-$255.26M
EBITDA
-$97.72M
Free cash flow
-$158.22M
Per share
Balance sheet
Liquidity
EPS
-$5.94
EPS diluted
-$5.94
Free cash flow per share
-$2.06
Book value per share
-$13.71
Revenue per share
$11.71
TBVPS
$18.58
Total assets
$1.84B
Total liabilities
$2.9B
Debt
$400.21M
Equity
-$1.05B
Working capital
$670.84M
Debt to equity
-0.38
Current ratio
2.1
Quick ratio
1.99
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
-10.8%
Gross margin
92.2%
Net margin
-50.3%
Operating margin
-14.6%
Return on assets
-24.4%
Return on equity
N/A
Return on invested capital
-38.4%
Return on capital employed
-20.7%
Return on sales
-28.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTCT stock price
How has the Ptc Therapeutics stock price performed over time
Intraday
2.19%
1 week
-0.28%
1 month
10.2%
1 year
71.01%
YTD
67.78%
QTD
24.64%
Financial performance
How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$900.66M
Gross profit
$830.43M
Operating income
-$131.36M
Net income
-$453.2M
Gross margin
92.2%
Net margin
-50.3%
PTCT's operating margin has surged by 85% year-on-year and by 32% since the previous quarter
The company's operating income has surged by 83% YoY and by 32% QoQ
The company's net margin rose by 37% YoY and by 6% QoQ
The net income has grown by 29% YoY and by 5% from the previous quarter
Growth
What is Ptc Therapeutics's growth rate over time
Valuation
What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.82
The EPS is up by 31% year-on-year and by 6% since the previous quarter
Ptc Therapeutics's equity has shrunk by 57% YoY and by 8% QoQ
The price to sales (P/S) is 52% higher than the last 4 quarters average of 2.6 but 29% lower than the 5-year quarterly average of 5.6
Ptc Therapeutics's revenue has increased by 13% YoY
Efficiency
How efficient is Ptc Therapeutics business performance
The ROS has soared by 64% year-on-year and by 25% since the previous quarter
The ROIC has grown by 46% YoY and by 21% from the previous quarter
Ptc Therapeutics's ROA has increased by 44% YoY and by 13% from the previous quarter
Dividends
What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTCT.
Financial health
How did Ptc Therapeutics financials performed over time
The total assets is 36% less than the total liabilities
The quick ratio has surged by 112% year-on-year but it has declined by 5% since the previous quarter
Ptc Therapeutics's current ratio has surged by 91% YoY but it has decreased by 6% QoQ
The company's debt is 138% higher than its equity
PTCT's debt to equity has surged by 64% year-on-year and by 5% since the previous quarter
Ptc Therapeutics's equity has shrunk by 57% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.